RNA-triggered CRISPR kill switch & Hidden microproteins in human biology - News (May 7, 2026)

In medical research, scientists are reporting a powerful new way to selectively eliminate cells using CRISPR—by listening for RNA, not just targeting DNA. The enzyme, called Cas12a2, can be programmed so it only activates when it detects a chosen RNA transcript inside a cell. Once triggered, it essentially shreds DNA broadly, creating overwhelming damage that pushes cells toward shutdown and death. In tests, human cancer cells without the target RNA were largely spared, and the researchers say they saw little evidence of unintended activation under their conditions. As proof of concept, they targeted HPV cancer transcripts and even showed reduced growth in HPV16-positive patient-derived tumors in mice after local delivery. The bigger story is what this enables: a programmable, RNA-defined “remove these cells” tool—though delivery and safety will determine how far it goes.

Staying in biology, researchers are also expanding what we even count as a “human protein.” Teams mapping the so-called dark proteome are finding thousands of tiny microproteins produced from genome regions long written off as noncoding. Using approaches that reveal what ribosomes are actually translating, they’ve uncovered microproteins linked to essentials like cell division and DNA repair—and intriguingly, some that appear more specific to cancer cells. A particularly interesting angle is that some of these microproteins may show up on tumor cell surfaces, which could make them visible targets for immune-based therapies. The headline here is simple: human biology is bigger than our old protein catalogs, and that opens up fresh terrain for understanding disease—and eventually, new drug targets.

And on the treatment front, one experimental drug is putting a rare jolt of optimism into advanced pancreatic cancer, a disease notorious for late detection and limited options. A drug called daraxonrasib, added to standard chemotherapy, reportedly roughly doubled overall survival in early Phase 3 results—about 13 months compared with roughly 7 months for chemo alone. Another study also posted encouraging survival figures in heavily pretreated patients at the highest dose. The FDA has fast-tracked the therapy and is allowing expanded access while review continues. The catch is tolerability: severe rash and other side effects were common, and some patients had to pause or stop. Still, if these results hold up, it could reshape standard care—and potentially influence treatment strategies for other cancers tied to RAS mutations.

Turning to geopolitics and global trade, France says it’s moving the Charles de Gaulle aircraft carrier strike group south of the Suez Canal into the Red Sea, positioning it for a possible French-British defensive mission connected to maritime security near the Strait of Hormuz. With the strait effectively shut amid the Iran war, hundreds of ships are stuck and energy markets are under intense pressure—an interruption the International Energy Agency has called unprecedented. French officials emphasize this would be separate from the U.S. effort and framed as defensive under international law, with the goal of restoring confidence for shipowners and insurers facing soaring war-risk premiums. Whether it materializes depends on conditions easing, industry willingness to resume transits, and consent from neighboring states—including Iran. The bigger signal: Europe is trying to protect critical trade routes while keeping diplomatic leverage in play.

In Europe’s internal security picture, Western intelligence services are warning that Russia has escalated attempted targeted killings across the continent since the invasion of Ukraine—moving beyond defectors to include activists and foreign supporters of Ukraine. Investigators in France say Russian men conducted surveillance last year near the home of a prominent Russia-focused human-rights activist living under police protection, in what’s suspected to be preparation for an attack. Other countries have disrupted alleged plots against activists, defense-industry figures, Ukrainian officials, and even President Zelenskyy. Officials say the operations increasingly rely on criminal proxies, a shift they link to earlier expulsions of Russian diplomats that made direct operations harder. Even failed attempts can do their job by spreading fear and draining law-enforcement resources, investigators argue—while Russia denies involvement.

Now to the fast-moving world of AI adoption, where one of the most striking trends is scale—not just in labs, but in daily life. Reporting this week frames China as a massive, real-world testing ground for generative and “agentic” AI, with crowds in major cities seeking help installing tools and integrating them into routine tasks like travel planning, ordering food, hiring, and health monitoring. Government figures cited in the story put China at more than 600 million generative-AI users as of December, sharply higher than the prior year. And usage intensity appears to be rising too, with data cited suggesting Chinese models’ weekly consumption has recently surpassed U.S. models—an indicator of how quickly tools are being normalized at street level. Export controls on advanced chips remain a constraint, but analysts argue they may also push faster domestic coordination and innovation. The global takeaway is about expectations: China’s approach to deploying AI inside a tightly controlled internet could influence how products are built—and how governance is justified—worldwide.

That broader AI boom is also colliding with the courts. Bestselling author Scott Turow and several major publishers have filed a class-action lawsuit accusing Meta of copyright infringement tied to training its Llama AI models. The claim is that Meta knowingly pulled in millions of copyrighted books and journal articles from piracy-linked sources instead of licensing them, and then leaned on a “fair use” strategy. The plaintiffs are seeking damages and an injunction, including destruction of allegedly infringing copies, while Meta says it will fight and notes that some courts have supported fair-use arguments for AI training. What makes this case especially consequential is the piracy allegation: judges may treat “transformative use” very differently if the underlying dataset was acquired from illicit sources rather than negotiated access.

Another AI-related concern is moving from theory to everyday harm: deepfakes are getting good enough that basic common sense cues no longer work. Experts point to cases like a robocall mimicking President Joe Biden ahead of New Hampshire’s 2024 primary as a vivid warning for election interference, but the problem isn’t limited to politics. Schools and local officials have also dealt with deepfake incidents involving students, and researchers say real-time deepfakes on video calls are becoming more common—raising the risk of impersonation scams and reputational attacks. New Hampshire has a criminal defamation law aimed at deepfakes, but enforcement is still limited. The practical advice from experts is less about learning to spot tiny visual glitches and more about verification: rely on trusted channels, confirm surprising requests offline, and use prearranged authentication methods when identity really matters.

Finally, in the markets, the AI race is reshuffling who investors see as the top winner. Alphabet is closing in on Nvidia’s position as the world’s most valuable company, fueled by a strong rally tied to its AI push and rapid growth in Google Cloud. Alphabet’s cloud revenue jumped sharply in the latest quarter, and investors are also buying into its story as both an AI services powerhouse and a builder of custom AI chips that attract major customers. Nvidia remains central to AI computing demand, but Alphabet’s momentum hints at a broader shift: markets may be leaning toward companies that can turn AI into recurring enterprise spending at platform scale, not just the companies selling the picks and shovels. If Alphabet retakes the top spot, it will be a symbolic marker of that transition.